Masitinib

Masitinib Slows Disability Progression in PPMS, Non-active SPMS

Masitinib, AB Scienceā€™s experimental oral therapy, significantly slows disability progression in adults with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS), according to final data from the AB07002 Phase 2b/3 clinical trial. These findings, indicating that the trial met its main goal, support…

Sweden, Like France, OKs Start of Masitinib Trial in Progressive MS

The Swedish Medical Products Agency has approved AB Scienceā€™s request to launch in the country a confirmatory Phase 3 clinical trial of its lead candidate masitinibĀ in adults withĀ primary progressive multiple sclerosisĀ (PPMS) and nonactiveĀ secondary progressive MSĀ (SPMS). The decision comes on the heels of a similar authorization byĀ the…

#MSVirtual2020 – Masitinib Delays Disability Progression in PPMS, Non-active SPMS

AB Scienceā€™s lead candidate masitinibĀ safely and effectively delays disability progression in people withĀ primary progressive multiple sclerosisĀ (PPMS) and non-activeĀ secondary progressive MSĀ (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…

Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says

Genentech‘sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosisĀ (SPMS) amongĀ U.S. neurologists, even though Novartis’Ā MayzentĀ (siponimod) and EMD Serono’sĀ MavencladĀ (cladribine) were approved in March to treat this same MS…

Kinase Inhibitor, Masitinib, Spotted for Potential to Treat Neurological Disorders Like PPMS

AB ScienceĀ recently reported the publication of four peer-reviewed and independent research papers that add to the growing recognition of masitinib, the companyā€™s lead compound, as a promising treatment for neurological and neurodegenerative diseases, including progressive multiple sclerosis (MS), Alzheimerā€™s disease (AD), and amyotrophic lateral sclerosis (ALS). Tyrosine kinase inhibitors (TKIs)…

Neuroprotective Qualities of Masitinib Drug in Stroke Encouraging For MS Indication

An encouraging experimental drug that is being developed for Multiple Sclerosis continues to show promise in being able to offer neuroprotective benefits — an effect that could slow and eventually cure MS.Ā Masitinib,Ā which is being developed by AB Science forĀ numerous neurological indications, including Alzheimer’s disease, progressive multiple sclerosis, and amyotrophic…